Stay updated with breaking news from Service Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Denny Jacob Allarity Therapeutics shares rise 15%, to 69 cents, following initial results from its continuing clinical trial evaluating the efficacy of...
By Adriano Marchese Shares of NeuroSense Therapeutics were lower after it said trials for its ALS treatment met primary safety and tolerability endpoints, as...
Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.
EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.
The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.